Comparison of $^{11}$C-Choline and $^{18}$F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer

Remke M. Pieterman, MD$^{1,2}$; Tijn H. Que, MD$^1$; Philip H. Elsinga, PhD$^1$; Jan Pruijm, MD$^1$; John W.G. van Putten, MD$^2$; Antoon T.M. Willemsen, PhD$^1$; Willem Vaalburg, PhD$^1$; and Harry J.M. Groen, MD$^2$

$^1$PET Center, Groningen University Hospital, Groningen, The Netherlands; and $^2$Department of Pulmonary Diseases, Groningen University Hospital, Groningen, The Netherlands

PET with $^{18}$F-FDG is used for detection and staging of thoracic cancer; however, more specific PET radiopharmaceuticals would be welcome. $^{11}$C-labeled choline (CHOL) is a new radiopharmaceutical potentially useful for tumor imaging, since it is incorporated into cell membranes as phosphatidylcholine. The aim of this study was to investigate whether $^{11}$C-CHOL PET has advantages over $^{18}$F-FDG PET in patients with thoracic cancer.

**Methods:** We evaluated 17 patients with thoracic cancer both with $^{11}$C-CHOL PET and $^{18}$F-FDG PET. After transmission scanning, $^{11}$C-CHOL was injected intravenously, and whole-body scanning was started after 5 min. Immediately thereafter, $^{18}$F-FDG was injected intravenously, followed after 90 min by interleaved attenuation-corrected whole-body scanning. Scans were performed from crown to femur. Visual and quantitative (standardized uptake value) analyses of $^{11}$C-CHOL PET and $^{18}$F-FDG PET were performed and compared with results of traditional staging and follow-up.

**Results:** The most prominent features of normal $^{11}$C-CHOL distribution were high uptake in liver, renal cortex, and salivary glands. Except for some uptake in choroid plexus and pituitary gland, brain uptake was negligible. All primary thoracic tumors were detected with $^{11}$C-CHOL PET and $^{18}$F-FDG PET. Both $^{11}$C-CHOL PET and $^{18}$F-FDG PET correctly identified all 16 patients with lymph node involvement. However, in a lesion-to-lesion analysis, $^{11}$C-CHOL PET detected only 29 of 43 metastatic lymph nodes, whereas $^{18}$F-FDG PET detected 41 of 43. $^{11}$C-CHOL PET detected fewer intrapulmonary and pleural metastases than $^{18}$F-FDG PET (27/47 vs. 46/47). More brain metastases were detected with $^{11}$C-CHOL PET (23/23) than with $^{18}$F-FDG PET (3/23). For primary tumors, the median (range) standard uptake values of $^{11}$C-CHOL and $^{18}$F-FDG were 1.68 (0.98–3.22) and 4.22 (1.40–8.26), respectively ($P = 0.001$).

**Conclusion:** $^{11}$C-CHOL PET can be used to visualize thoracic cancers. Although detection of lymph node metastases with $^{11}$C-CHOL PET was inferior compared with $^{18}$F-FDG PET, the detection of brain metastases was superior.

**Key Words:** $^{11}$C-choline; $^{18}$F-FDG; PET; thoracic cancer; metastasis

tion of the radiopharmaceutical to increase tumor-to-background contrast.

Considering the ability of thoracic cancers to metastasize locoregionally and hematogenously, a whole-body PET scan to stage the disease is appealing. The aim of this study was to determine the feasibility of whole-body $^{11}$C-CHOL PET for detection of primary thoracic cancers and their metastases, and to compare this technique to whole-body $^{18}$F-FDG PET.

**MATERIALS AND METHODS**

**Patients**

The study population consisted of 17 patients with histologically proven thoracic cancer. Tumor size was determined by measuring the 2 largest perpendicular dimensions on a representative transverse CT slice. The minimum diameter of the primary tumor was 1 cm. Medistinal and distant metastases were evaluated by invasive procedures such as mediastinoscopy, guided biopsy of suspected distant lesions, or subsequent imaging of growing lesions (CT, MRI, sonography, or $^{99m}$Tc-diphosphonate bone scintigraphy). Patients were studied before start of treatment with chemotherapy or radiotherapy. Excluded from the study were patients with hyperglycemia before the PET study (serum glucose $\geq 10$ mmol/L (180 mg/dL).

The medical ethics committee of Groningen University Hospital approved the study protocol. All patients gave written informed consent.

**Data Acquisition**

All studies were performed using an ECAT EXACT HR+ (Siemens/CTI Inc., Knoxville, TN). This camera acquires 63 planes simultaneously over a 15.5-cm field of view. In-plane resolution is approximately 4.3 mm, with an axial resolution of approximately 4.1 mm full width at half maximum (15).

$^{18}$F-FDG was synthesized according to Hamacher et al. (16) by an automated synthesis module (17). $^{11}$C-CHOL was synthesized according to Hara et al. (14) by the reaction of $^{11}$C-methyl iodide with dimethylaminoethanol at 100°C for 5 min. Unreacted substrates were removed by evaporation, and $^{11}$C-CHOL was further purified using a cation-exchange resin. The resulting product was dissolved in saline. Both radiopharmaceuticals were sterile and their radiochemical purity was $\geq 95\%$.

Patients were instructed to fast for at least 6 h before imaging to minimize nonspecific uptake of $^{18}$F-FDG and $^{11}$C-CHOL in normal tissue (9,18). They were also instructed to drink at least 1 liter of water before imaging to stimulate $^{18}$F-FDG excretion from the renal calyces and subsequent voiding. A venous canula was inserted in the forearm for injection of the radiopharmaceuticals. From this canula, a 2-ml blood sample was also drawn to measure serum glucose level.

After positioning the patient in the camera, transmission scanning using a $^{68}$Ge/$^{68}$Ga ring source was performed from crown to femur for 3 min per bed position to correct for attenuation of the photons by the body tissues. This was immediately followed by intravenous injection of 800 MBq $^{11}$C-CHOL. After a 5-min interval, whole-body scanning was performed over the same area for 5 min per bed position. $^{18}$F-FDG was injected intravenously immediately thereafter (400 MBq in patients with body weight $<85$ kg; 600 MBq in patients with body weight $>85$ kg). Ninety minutes after $^{18}$F-FDG injection (130 min after $^{11}$C-CHOL administration), interleaved attenuation-corrected whole-body scanning was performed from crown to femur with 3 and 5 min per bed position for transmission and emission scanning, respectively. Data from multiple bed positions were iteratively reconstructed (ordered subset expectation maximization) into attenuated and nonattenuated $^{11}$C-CHOL and $^{18}$F-FDG whole-body PET images (19).

**Data Analysis**

Non-attenuation-corrected $^{11}$C-CHOL PET and $^{18}$F-FDG PET images were qualitatively compared for their uptake in malignant lesions and normal anatomical structures by 2 experienced PET physicians unaware of patients' clinical data. If they could not reach consensus, the opinion of a third independent observer was sought. Because detection or exclusion of malignant lesions rather than determination of quantitative parameters was the main goal of this PET study, only non-attenuation-corrected PET images were used for qualitative analysis. The physicians interpreted any hot spots as either benign or malignant.

To compare the results of $^{11}$C-CHOL PET, $^{18}$F-FDG PET, and histological data, mediastinal hot spots were located according to the Mountain and Dresler classification of regional lymph nodes (20). Hot spots outside the mediastinum were described according to anatomical location.

Standardized uptake value (SUV) was calculated for malignant primary lesions from regions of interest (ROI) obtained from the attenuation-corrected images. SUV provided a measure of tracer concentration in the ROI relative to its uniform distribution over the body. SUV depends, among other things, on patient habitus; to minimize this source of variability, a correction of SUV was made for lean body mass (21). Using ECAT/CAPP software (Siemens/CTI Inc.), SUVs were calculated in the transaxial plane in which the tumor had the highest activity. By using the isocountour tool adjusted to 70% of the peak counts in the lesion, an ROI was drawn from the part of the tumor with the highest activity in a standardized manner.

**Statistical Analysis**

The degree of interobserver agreement was quantified with the $\kappa$ statistic. To compare $^{11}$C-CHOL and $^{18}$F-FDG SUVs of primary lung tumors, Wilcoxon’s signed rank test was used. The correlation coefficient between $^{18}$F-FDG and $^{11}$C-CHOL SUVs was calculated using 1-tailed Pearson’s test. A probability of $\leq 0.05$ was considered statistically significant. Statistical analysis was performed with SPSS software (Statistical Product and Service Solutions Inc., Chicago, IL).

**RESULTS**

**Patients**

A total of 17 patients were included in this study; their characteristics are shown in Table 1. Tumor diameter varied between 2 and 8.5 cm. All 17 patients received 800 MBq $^{11}$C-CHOL according to the protocol; 14 patients received 400 MBq $^{18}$F-FDG, and the other 3 patients received 600 MBq $^{18}$F-FDG.

**Physiological Body Distribution of $^{11}$C-CHOL**

$^{11}$C-CHOL PET produced easily interpretable images. The most prominent physiological uptake of tracer was observed in the liver, renal cortex, and salivary glands. Less
intense uniform tracer uptake was present in the lungs, spleen, skeletal muscles, and bone marrow. Variable $^{11}$C-CHOL uptake was observed in the pancreatic region, and a linear uptake configuration in the abdomen was identified as the small intestine. In 2 patients, mild uptake of $^{11}$C-CHOL was observed in the thyroid gland. Uptake of tracer in the brain was negligible; however, mild tracer uptake was observed in the choroid plexus and pituitary gland. No uptake was observed in the mediastinum and myocardium. A clear distinction could be made between the mediastinum and the lungs. In 2 patients, accumulation of $^{11}$C-CHOL in the bladder was observed.

The whole-body distribution of $^{18}$F-FDG has been described previously (22). A similar pattern was observed in this study.

Detection of Lesions with $^{11}$C-CHOL PET and $^{18}$F-FDG PET

**Interobserver Agreement.** With respect to hot spot detection from $^{11}$C-CHOL PET images, the degree of interobserver agreement ($\kappa$) was 0.93 (95% confidence interval [CI]; range, 0.87–0.99). For $^{18}$F-FDG PET images, agreement was 0.96 (95% CI; range, 0.91–1.00). Visually, $^{11}$C-CHOL uptake in malignant lesions often appeared remarkably less intense than that of $^{18}$F-FDG.

**Detection of Primary Thoracic Tumors.** Both $^{11}$C-CHOL PET and $^{18}$F-FDG PET detected all 17 primary thoracic tumors (Table 2). In 4 patients the $^{11}$C-CHOL hot spot appeared as a circular lesion with a rim of mild uptake and a central large defect. The matching $^{18}$F-FDG hot spots appeared as circular lesions with intense increased uptake and central localized small defects.

**Detection of Lymphatic Metastases.** Ten patients were diagnosed with mediastinal lymph node metastases. In all

### TABLE 1
Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y) (median [range]), 58 (45–73)</td>
<td></td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>13/4</td>
</tr>
<tr>
<td>Histology primary tumor</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>5</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>Large cell carcinoma</td>
<td>5</td>
</tr>
<tr>
<td>Small cell lung cancer</td>
<td>2</td>
</tr>
<tr>
<td>Malignant mesothelioma</td>
<td>3</td>
</tr>
<tr>
<td>Stage of disease*</td>
<td></td>
</tr>
<tr>
<td>Non–small cell lung cancer</td>
<td></td>
</tr>
<tr>
<td>T1N0-1M0</td>
<td>2</td>
</tr>
<tr>
<td>T3-4N2M0</td>
<td>3</td>
</tr>
<tr>
<td>T2-4N0-3M1</td>
<td>7</td>
</tr>
<tr>
<td>Small cell lung cancer Extensive disease</td>
<td>2</td>
</tr>
<tr>
<td>Malignant mesothelioma T2N0M0</td>
<td>1</td>
</tr>
<tr>
<td>T3N3M0</td>
<td>1</td>
</tr>
<tr>
<td>T2N2M1</td>
<td>1</td>
</tr>
</tbody>
</table>

*The pathological tumor-nodes-metastasis (TNM) system of classification of the American Joint Committee on Cancer was used (40).

**TABLE 2**
Lesions Detected with $^{11}$C-CHOL PET and $^{18}$F-FDG PET Compared with Traditional Staging and Follow-Up*

<table>
<thead>
<tr>
<th>Localization</th>
<th>Lesions detected with</th>
<th>Traditional staging and follow-up</th>
<th>$^{11}$C-CHOL PET</th>
<th>$^{18}$F-FDG PET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of patients</td>
<td>No. of patients</td>
<td>No. of patients</td>
<td>No. of patients</td>
</tr>
<tr>
<td>Primary tumor</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>Mediastinal lymph node</td>
<td>10</td>
<td>33</td>
<td>10</td>
<td>21</td>
</tr>
<tr>
<td>Supraclavicular/axillary lymph node</td>
<td>6</td>
<td>10</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>2*</td>
<td></td>
<td>2*</td>
<td></td>
</tr>
<tr>
<td>Intrapulmonary/pleural</td>
<td>7</td>
<td>47</td>
<td>7</td>
<td>27</td>
</tr>
<tr>
<td>Skeleton</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Liver</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Brain</td>
<td>3</td>
<td>23</td>
<td>3</td>
<td>23</td>
</tr>
</tbody>
</table>

*Includes history, physical examination, laboratory tests, chest radiography, CT of thorax (including liver and adrenal glands), bronchoscopy with biopsy, mediastinoscopy, and, if applicable, thoracotomy. Patients with signs of distant metastases received additional imaging tests and biopsies.

†TP = true-positive; FP = false-positive.

‡Patient had false-positive and true-positive hot spots.
these patients, both $^{11}$C-CHOL PET and $^{18}$F-FDG PET detected mediastinal hot spots (Table 2). With surgical procedures, a total of 33 metastatic mediastinal lymph node stations were confirmed: $^{18}$F-FDG PET detected 31 of the 33 (94%), while $^{11}$C-CHOL PET detected only 21 of 33 (64%) (Fig. 1). Both $^{11}$C-CHOL PET and $^{18}$F-FDG PET were false-positive at 1 mediastinal lymph node station in the same patient. At another mediastinal lymph node station, $^{11}$C-CHOL PET, but not $^{18}$F-FDG PET, was false-positive.

Both $^{11}$C-CHOL PET and $^{18}$F-FDG PET were correct in detecting all 6 patients with supraclavicular or axillary lymph node metastases. A total of 10 cytologically proven supraclavicular or axillary lymph node metastases were found, of which $^{11}$C-CHOL PET detected 8 (80%) while $^{18}$F-FDG PET detected all (100%). At 1 supraclavicular lymph node site, both $^{11}$C-CHOL PET and $^{18}$F-FDG PET were false-positive.

**Detection of Hematogenic Metastases.** Both $^{11}$C-CHOL PET and $^{18}$F-FDG PET correctly detected all 7 patients with intrapulmonary or pleural metastases (range, 1–23 metastases) (Table 2). In 1 patient, both $^{11}$C-CHOL PET and $^{18}$F-FDG PET were false-positive for 1 intrapulmonary hot spot. With $^{11}$C-CHOL PET, hot spots were observed at 27 of 47 (57%) intrapulmonary or pleural metastatic sites; with $^{18}$F-FDG PET, hot spots were observed at 46 of 47 (98%) sites.

In 1 patient, bone scintigraphy revealed 4 bone metastases; both $^{11}$C-CHOL PET and $^{18}$F-FDG PET detected skeletal hot spots at the same locations. In a second patient, $^{11}$C-CHOL PET revealed hot spots in the right humerus and right pelvic bone, while $^{18}$F-FDG PET only revealed a hot spot in the right humerus. Bone scintigraphy revealed no suspicious skeletal lesions at all.

An adrenal gland metastasis in 1 patient and 2 liver metastases in another patient were confirmed; these were correctly diagnosed by $^{18}$F-FDG PET but not detected by $^{11}$C-CHOL PET. In 1 patient, both $^{11}$C-CHOL PET and $^{18}$F-FDG PET were false-positive for a hot spot ranked as an adrenal gland metastasis.

CT or MRI detected 23 brain metastases in 3 patients. $^{11}$C-CHOL PET was able to detect all brain metastases (100%), whereas $^{18}$F-FDG PET only detected 3 (13%).

**FIGURE 2.** PET SUVs of $^{11}$C-CHOL and $^{18}$F-FDG of primary tumors in patients with thoracic cancer.
SUV Analysis

SUVs (corrected for lean body mass) of the primary lung tumor are presented in Figure 2. Apart from 1 patient, SUVs were higher for \(^{18}\text{F}-\text{FDG}\) than for \(^{11}\text{C}-\text{CHOL}\). The median (range) of SUVs were 1.68 (0.98–3.22) for \(^{11}\text{C}-\text{CHOL}\) and 4.22 (1.40–8.26) for \(^{18}\text{F}-\text{FDG}\) \((P = 0.001)\). The \(^{11}\text{C}-\text{CHOL}\) SUV and \(^{18}\text{F}-\text{FDG}\) SUV of primary tumors were only weakly correlated (correlation coefficient, 0.47; \(P = 0.03\)).

DISCUSSION

The most widely applied PET radiopharmaceutical in oncology is \(^{18}\text{F}-\text{FDG}\). Although \(^{18}\text{F}-\text{FDG}\) PET studies have additional value in detection, staging, and treatment monitoring in a variety of neoplasms (23), \(^{18}\text{F}-\text{FDG}\) PET is not 100% accurate in the detection of primary tumors and their metastases (24). Therefore, more specific PET radiopharmaceuticals are needed.

Choline is transported into cells and acts as a precursor for the biosynthesis of phospholipids, which are membrane elements (10). Cancer is associated with cell proliferation and upregulation of the enzyme choline kinase (which catalyzes the phosphorylation of choline in the pathway for biosynthesis of phospholipids) (25), providing the rationale for the use of \(^{11}\text{C}-\text{CHOL}\) as a radiopharmaceutical in oncological PET studies. In the brain and prostate, organs in which \(^{18}\text{F}-\text{FDG}\) PET lacks sensitivity, \(^{11}\text{C}-\text{CHOL}\) PET showed considerable potential for the detection and staging of tumors (14,26).

PET tumor detection depends on the tumor-to-nontumor uptake ratio. Although background uptake of \(^{11}\text{C}-\text{CHOL}\) and \(^{18}\text{F}-\text{FDG}\) in the lung was uniform, \(^{11}\text{C}-\text{CHOL}\) uptake in malignant lesions was lower compared with \(^{18}\text{F}-\text{FDG}\). The uptake of \(^{11}\text{C}-\text{CHOL}\) in tumors represents membrane synthesis, whereas \(^{18}\text{F}-\text{FDG}\) uptake represents glycolysis. However, \(^{18}\text{F}-\text{FDG}\) is also taken up by inflammatory cells such as macrophages (6). Large cavitating lung tumors may be associated with a rim of inflammatory cells with elevated \(^{18}\text{F}-\text{FDG}\) uptake surrounding a necrotic tumor region. Tumor hypoxia also affects cellular tracer uptake. Tumor hypoxia increases cellular uptake of \(^{18}\text{F}-\text{FDG}\), while the uptake of other substrates (e.g., amino acids) is decreased (27). Similarly, we observed reduced uptake of \(^{11}\text{C}-\text{CHOL}\) in tumor areas that were presumed to be hypoxic.

The occurrence of locoregional or distant metastases has a profound effect on the survival of patients with thoracic cancer. Normal tracer accumulation in various organs hampers the detection of metastases with PET in these organs. In the case of \(^{11}\text{C}-\text{CHOL}\), free intracellular choline is not only phosphorylated, but it can also be oxidized to betaine aldehyde (10). Since the liver and kidney are major sites for choline oxidation, they exhibit a high background uptake (26,28). For this reason, liver and adrenal gland metastases were not detected by \(^{11}\text{C}-\text{CHOL}\) PET nearly as well as by \(^{18}\text{F}-\text{FDG}\) PET. The enhanced uptake of \(^{11}\text{C}-\text{CHOL}\) observed in the pancreas and intestine of several patients may be due to secretion of phospholipid-rich pancreatic juice and bile (9,26,29).

Consistent with previously reported data (14,30), \(^{11}\text{C}-\text{CHOL}\) PET was very effective in detecting brain metastases. \(^{11}\text{C}-\text{CHOL}\) penetrates the blood–brain barrier by the amine-specific transport system (31), followed by a rapid brain washout (28). Disruption of the blood–brain barrier is observed in brain tumors and metastases, and this may facilitate increased \(^{11}\text{C}-\text{CHOL}\) uptake for cell membrane synthesis. Incorporation of \(^{11}\text{C}-\text{CHOL}\) in the endothelium of cerebral blood vessels present in the choroid plexus and pituitary gland (32), which do not have a blood–brain barrier, may explain the increased uptake at these sites. Because of the excessive uptake of glucose in the brain, a routine whole-body \(^{18}\text{F}-\text{FDG}\) PET lacks the sensitivity to detect brain metastases. Other \(^{11}\text{C}\)-labeled radiopharmaceuticals used for the evaluation of brain tumors include \(^{11}\text{C}\)-methionine and \(^{11}\text{C}\)-tyrosine (33,34). In the detection of brain tumors, \(^{11}\text{C}-\text{CHOL}\) may be preferred to amino acids due to its higher tumor-to-background ratio (14). The detection of bone (marrow) metastases with \(^{11}\text{C}-\text{CHOL}\) PET and \(^{18}\text{F}-\text{FDG}\) PET in this study was consistent with the literature (26,35,36). In 2 patients \(^{11}\text{C}-\text{CHOL}\) uptake in the urinary bladder was observed. This urinary accumulation of \(^{11}\text{C}-\text{CHOL}\) may be the result of incomplete tubular reabsorption of intact tracer or enhanced excretion of labeled oxidative metabolites (9), as was also suggested by DeGrado et al. (37), who saw accumulation in the bladder while using \(^{18}\text{F}\)-labeled choline.

\(^{11}\text{C}-\text{CHOL}\) PET and \(^{18}\text{F}-\text{FDG}\) PET were equally accurate in detecting lymph node metastases. However, on a lesion-to-lesion basis, \(^{11}\text{C}-\text{CHOL}\) PET was less sensitive than \(^{18}\text{F}-\text{FDG}\) PET. Our observations contrast with those of Hara et al. (38), who observed 100% sensitivity for \(^{11}\text{C}-\text{CHOL}\) PET and 75% sensitivity for \(^{18}\text{F}-\text{FDG}\) PET in detecting mediastinal lymph node metastases originating from non–small cell lung cancer. This may be partly explained by the low SUV threshold used by Hara et al., as they defined a 40% difference from the SUV of the primary tumor as positive for mediastinal lymph node metastasis. This will easily lead to a high sensitivity for \(^{11}\text{C}-\text{CHOL}\) PET. Their low sensitivity of \(^{18}\text{F}-\text{FDG}\) PET could be explained by the short interval of 40 min between the injection of \(^{18}\text{F}-\text{FDG}\) and the onset of scanning. Tumor concentrations of \(^{18}\text{F}\)-FDG do not reach a plateau until 90 min after intravenous injection (39).

Consistent with previous reports, \(^{11}\text{C}-\text{CHOL}\) PET gave clear images with good contrast at 5 min after injection (26,35). After intravenous injection, tissue uptake and blood clearance is rapid, and the tissue-to-background ratio remains essentially constant over 30 min (9,35). Although the short half-life of \(^{11}\text{C}\)-labeled radiopharmaceuticals could limit the applicability of whole-body scanning, we found that PET with 800 MBq \(^{11}\text{C}-\text{CHOL}\) was feasible in practice to obtain images from crown to femur in thoracic cancer patients. According to our acquisition protocol, the \(^{18}\text{F}-\text{FDG}\)
scan was started 130 min after the $^{11}$C-CHOL injection, which is more than 6 half-lives of $^{11}$C. It can be assumed that $^{18}$F-FDG scanning is not contaminated by residual $^{11}$C radioactivity. Whole-body PET to stage thoracic cancer is appealing considering the ability of this disease to metastasize locoregionally and hematogenously.

CONCLUSION

Visual analysis of whole-body $^{11}$C-CHOL PET was less accurate than that of whole-body $^{18}$F-FDG PET for the detection of metastases in thoracic cancer patients due to the lower accumulation of $^{11}$C-CHOL in malignant tissue. The inferiority of $^{11}$C-CHOL PET was most notable in the detection of lymph node metastases. However, for the detection of brain metastases, $^{11}$C-CHOL PET was superior to $^{18}$F-FDG PET.

REFERENCES

Comparison of $^{11}$C-Choline and $^{18}$F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer

Remge M. Pieterman, Tijn H. Que, Philip H. Elsinga, Jan Pruim, John W.G. van Putten, Antoon T.M. Willemsen, Willem Vaalburg and Harry J.M. Groen


This article and updated information are available at:
http://jnm.snmjournals.org/content/43/2/167

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml